Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

Collaborators (255)

Rossouw J, Ludlam S, McGowan J, Geller N, Ford L, Prentice R, Anderson G, LaCroix A, Patterson R, McTiernan A, Cochrane B, Hunt J, Tinker L, Kooperberg C, McIntosh M, Wang CY, Chen C, Bowen D, Kristal A, Stanford J, Urban N, Weiss N, White E, Stein E, Laskarzewski P, Cummings SR, Nevitt M, Palermo L, Harnack L, Cammarata F, Lindenfelser S, Psaty B, Heckbert S, Wassertheil-Smoller S, Frishman W, Wylie-Rosett J, Barad D, Freeman R, Rajkovic A, Hays J, Young R, Sangi-Haghpeykar H, Manson JE, Rexrode KM, Walsh B, Gaziano JM, Bueche M, Eaton CB, Cyr M, Sloane G, Assaf A, Phillips LS, Butler V, Porter V, Beresford SA, Taylor VM, Woods NF, Henderson M, Andersen R, Martin L, Hsia J, Gaba N, Katz R, Chlebowski R, Detrano R, Nelson A, Geller M, LeBlanc E, Michael Y, Whitlock E, Stevens V, Karanja N, Caan B, Sidney S, Bailey G, Hirata J, Kotchen JM, Barnabei V, Kotchen TA, Gilligan MA, Neuner J, Howard BV, Adams-Campbell L, Lessin L, Iglesia C, Mickel LK, Van Horn L, Greenland P, Khandekar J, Klein L, Rosenberg C, Black H, Powell L, Mason E, Gulati M, Stefanick ML, Hlatky MA, Chen B, Stafford RS, Mackey S, Lane D, Granek I, Lawson W, Messina C, San Roman G, Jackson R, Harris R, Paskett E, Mysiw WJ, Blumenfeld M, Lewis CE, Oberman A, Shikany JM, Safford M, Thomson CA, Bassford T, Ritenbaugh C, Chen Z, Ko M, Wactawski-Wende J, Trevisan M, Smit E, Millen A, LaMonte M, Robbins J, Yasmeen S, Qi L, Hubbell FA, Frank G, Wong N, Greep N, Monk B, Nathan L, Heber D, Elashoff R, Liu S, Langer RD, Criqui MH, Talavera GT, Garland CF, Allison MA, Gass M, Watts N, Limacher M, Perri M, Kaunitz A, Williams RS, Brinson Y, Curb JD, Petrovitch H, Rodriguez B, Masaki K, Blanchette P, Wallace R, Torner J, Johnson S, Snetselaar L, Robinson J, Ockene J, Rosal M, Ockene I, Yood R, Aronson P, Lasser N, Singh B, Lasser V, Kostis J, McGovern P, O'Sullivan MJ, Parker L, Potter J, Fernandez D, Caralis P, Margolis KL, Grimm RH, Perron MF, Levin JA, Brunner R, Graettinger W, Oujevolk V, Bloch M, Heiss G, Haines P, Ontjes D, Sueta C, Wells E, Kuller L, Cauley J, Milas NC, Johnson KC, Satterfield S, Li R, Connelly S, Tylavsky F, Brzyski R, Schenken R, Rodgers A, Budrys N, Sarto GE, Laube D, McBride P, Mares J, Loevinger B, Vitolins M, Burke G, Crouse R, Washburn S, Simon MS, Shumaker S, Rapp S, Legault C, Espeland M, Coker L, Naughton M, Rajkovic A, Cousins J, Hays J, Foreyt J, Assaf AR, Hall D, McNagny S, Henderson M, Patterson R, Miller V, Michael Y, Whitlock E, Valanis B, Hiatt R, Clifford C, Pottern L, Greenland P, Black H, Elliott W, Paskett E, Trevisan M, Oberman A, Bassford T, Moon T, Ritenbaugh C, Meyskens F Jr, Judd H, Gass M, Liu J, Watts N, Baum M, Grimm R, Daugherty S, Sheps D, Hulka B, Applegate W, Schenken R, Allen C, Bonds D, Burke G, Hendrix S.

Author information

  • 1Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-A410, PO 19024, Seattle, WA 98109. alacroix@whi.org.



The Women's Health Initiative Estrogen-Alone Trial was stopped early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned trial termination date. Postintervention health outcomes have not been reported.


To examine health outcomes associated with randomization to treatment with conjugated equine estrogens (CEE) among women with prior hysterectomy after a mean of 10.7 years of follow-up through August 2009.


The intervention phase was a double-blind, placebo-controlled, randomized clinical trial of 0.625 mg/d of CEE compared with placebo in 10,739 US postmenopausal women aged 50 to 79 years with prior hysterectomy. Follow-up continued after the planned trial completion date among 7645 surviving participants (78%) who provided written consent.


The primary outcomes were coronary heart disease (CHD) and invasive breast cancer. A global index of risks and benefits included these primary outcomes plus stroke, pulmonary embolism, colorectal cancer, hip fracture, and death.


The postintervention risk (annualized rate) for CHD among women assigned to CEE was 0.64% compared with 0.67% in the placebo group (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.75-1.25), 0.26% vs 0.34%, respectively, for breast cancer (HR, 0.75; 95% CI, 0.51-1.09), and 1.47% vs 1.48%, respectively, for total mortality (HR, 1.00; 95% CI, 0.84-1.18). The risk of stroke was no longer elevated during the postintervention follow-up period and was 0.36% among women receiving CEE compared with 0.41% in the placebo group (HR, 0.89; 95% CI, 0.64-1.24), the risk of deep vein thrombosis was lower at 0.17% vs 0.27%, respectively (HR, 0.63; 95% CI, 0.41-0.98), and the risk of hip fracture did not differ significantly and was 0.36% vs 0.28%, respectively (HR, 1.27; 95% CI, 0.88-1.82). Over the entire follow-up, lower breast cancer incidence in the CEE group persisted and was 0.27% compared with 0.35% in the placebo group (HR, 0.77; 95% CI, 0.62-0.95). Health outcomes were more favorable for younger compared with older women for CHD (P = .05 for interaction), total myocardial infarction (P = .007 for interaction), colorectal cancer (P = .04 for interaction), total mortality (P = .04 for interaction), and global index of chronic diseases (P = .009 for interaction).


Among postmenopausal women with prior hysterectomy followed up for 10.7 years, CEE use for a median of 5.9 years was not associated with an increased or decreased risk of CHD, deep vein thrombosis, stroke, hip fracture, colorectal cancer, or total mortality. A decreased risk of breast cancer persisted.


clinicaltrials.gov Identifier: NCT00000611.

Comment in

[PubMed - indexed for MEDLINE]
Free PMC Article

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms


Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Write to the Help Desk